PARP-inhibitor-based combination therapies, including chemotherapy, other targeted therapies, and radiotherapy, are currently under investigation for solid tumors, toward achieving an additive or synergistic outcome.30-32 For example, evidence suggests that PARP inhibitors act synergistically with immune checkpoint blockade to inhibit tumor growth by enhancing tumor mutational burden and programmed death ligand 1 expression.30,33 The preliminary signs of antitumor efficacy observed herein support testing of senaparib as part of a combination therapy. This evidence concerns the gene PARP1 and neoplasm.